Before starting Kesimpta, patients should be screened for hepatitis B and other infections. Vaccinations should be updated, and any live or live-attenuated vaccines should be administered at least four weeks before treatment begins. Pregnant or breastfeeding women should consult their healthcare providers to understand the potential risks, as the effects of Kesimpta on an unborn child or during lactation are not fully understood.